Tango Therapeutics reported preclinical efficacy for TNG‑456, a selective, MTA‑cooperative PRMT5 inhibitor showing antitumor activity in glioma and metastasis-prone tumors. The compound targets arginine methyltransferase pathways and is positioned for brain‑directed oncology applications where epigenetic vulnerabilities exist. Vivace Therapeutics disclosed VT‑3989, a TEAD inhibitor that suppressed aggressive, NF2‑deficient tumor growth in in vitro and in vivo models including meningioma. TEAD inhibitors aim to block YAP/TEAD transcriptional co‑activation in tumors reliant on Hippo pathway deregulation. Both programs remain in early development but underscore a continued push for targeted epigenetic and transcriptional modulators in hard-to-treat tumors, with brain-penetrant properties and differentiation from existing kinase-directed approaches.